Target protein for diabetes drug linked to reduced the risk of Alzheimer’s disease
2022
Karolinska Institutet, Stockholm, Sweden
A gene association study design was applied to examine the association between genetic variation in the targets of four anti-diabetic drug classes and Alzheimer´s disease AD risk. The researchers analysed data from over 300,000 participants in the UK Biobank register, as well as from more than 24,000 clinically diagnosed AD cases and 55,000 controls. The results show that genetic variation in sulfonylurea targets was associated with a lower risk of AD, and future studies are warranted to clarify the underlying mechanistic pathways between sulfonylureas and AD.
Genetic variation in targets of anti-diabetic drugs and Alzheimer disease risk: a Mendelian randomization study
Sara Hägg
Added on: 09-08-2022
[1] https://n.neurology.org/content/early/2022/06/02/WNL.0000000000200771[2] https://www.drugtargetreview.com/news/103341/target-protein-for-diabetes-drug-linked-to-reduce-the-risk-of-alzheimers-disease/?utm_source=Email+marketing&utm_medium=email&utm_campaign=DTR+-+Newsletter+24+-+Fluidigm+-+16.06.2022&utm_term=Target+protein+for+diabetes+drug+linked+to+reduce+the+risk+of+Alzheimer%e2%80%99s+disease&utm_content=https%3a%2f%2femails.drugtargetreview.com%2frussellpublishinglz%2f&gator_td=tooQK2klzq7GdGWSSwYR2UNot8f2vi%2b7lGwWCbga1TR6mebLQNio5H50MXtyLBeQu0ARAxq5tYjDwqrkg2bdV%2bqzioBeybD4hUmI3X%2bAqKBjTA%2bJdPpzc2aIbZfT8%2bZkj1heOUpP2KGN1wq3TDrpuG039WFXDA3lm%2bSuPxb4IyBfpJjFNSzM9eh5GKu%2fJXAxEI7zzVR47fE%2b%2fVIqjwubDud3pailKSMMCRUya3dFd60%3d
